10
Participants
Start Date
January 8, 2017
Primary Completion Date
October 9, 2017
Study Completion Date
March 30, 2018
BC-3781
Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
Quotient Clinical, Nottingham
Lead Sponsor
Collaborators (1)
Quotient Clinical
OTHER
Nabriva Therapeutics AG
INDUSTRY